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Abstract
Background: Modern drug therapy accounts for a major share of health expenditure and challenges public provider
resources. The objective of our study was to compare drug expenditure trends for ten major drug classes over 16 years
at Maccabi Healthcare Services (MHS), the 2nd largest healthcare organization in Israel.
Methods: A retrospective analysis of drug expenditure per HMO beneficiary between the years 1998–2014. Trends in
annual mean drug expenditures per MHS member were compared among 10 major drug classes.
Results: Average annual drug expenditure per beneficiary increased during the study period from 429.56 to 474.32 in
2014 (10.4 %). Ten drug classes accounted for 58.0 % and 77.8 % of total drug cost in 1998 and 2014, respectively. The
overall distribution of drug expenditure among drug classes differed significantly between 1998 and 2014 (p < 0.001),
mainly due to the increase in expenditure for cancer drugs, from 6.8 % of total drug cost to 30.3 %. In contrast,
expenditures for cardiovascular drugs decreased during the same period from 16.0 to 2.7 %. Moreover, the median
annual increase in net drug costs per HMO member during 1998–2014 was largest for cancer drugs (NIS 6.18/year; IQR,
1.70–9.92/year), about two-fold that of immunosuppressants, the second fastest growing drug class (NIS 2.81; IQR,
0.58–7.43/year).
Conclusions: The continuous rise in anti-cancer drug expenditure puts a substantial burden on the medication
budgets of public health organizations. Coordinated measures involving policy makers, physicians, and pharmaceutical
companies will be required for efficient cost containment.
Keywords: Drug expenditure, Cancer agents, Health Maintenance Organization
Abbreviations: HMO, Healthcare maintenance organization; IQR, Inter-quartile range; MHS, Maccabi healthcare
services; NIS, New Israeli Shekel; QALY, Quality adjusted life years
Background
Oncology drug cost, amounting to an estimated $40 bil-
lion per year worldwide, is a concerning issue in public
health economic discussions [1]. Medicare spending on
Part B drugs — a category dominated by drugs used to
treat cancer — increased from $3 billion in 1997 to $11
billion in 2004 (a 267 % increase), compared with a rise
in overall Medicare spending from $210 billion to $309
billion (an increase of 47 %) during the same period [2].
While 15 years ago the most expensive cancer drug was
paclitaxel (TAXOL®, Bristol-Myers Squibb) at a monthly
cost of approximately US$ 2,500 per patient in the USA,
some recently approved anti-cancer drugs are much
more expensive (http://www.ascopost.com/issues/febru-
ary-1,-2013/cost-of-cancer-drugs-what-price-for-what-
benefit.aspx). Trends in oncology drug expenditures,
especially in comparison with drugs for non-oncology
indications, have been only partially characterized. When
disclosed by health organizations, drug expenditure
often includes additional fees associated with the specific
medical condition such as hospital admission bills,
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surgeries and procedures, ambulatory care cost and sup-
portive therapy, all of which may vary widely among
countries [3–5].
Israel has national health insurance with universal
health coverage, i.e. every citizen is insured by one of
four health maintenance organizations (HMOs). The
budget of each HMO is allocated by the government
based on the number of beneficiaries. Medications and
health technologies and their precise indications covered
by the HMOs are determined by the Ministry of Health
and summarized in the “Health basket”. The government
decides on the annual growth rate of the health basket’s
budget, and once a year a professional committee priori-
tizes the addition of new medications or technologies
and their indications.
Maccabi Healthcare Services (MHS) is the second lar-
gest Israeli health organization, insuring about 2 million
beneficiaries in 2014 nationwide. Its health benefits in-
clude medications and technologies as specified by the
Israeli National Health Basket. Additionally, MHS pro-
vides new health technologies, including medications
with evidence-base technologies prior to their inclusion
in the National Health Basket. Our objective was to
compare trends in drug expenditure at a large modern
HMO over a 16-year- period, in major drug classes




All data regarding drug purchases (quantities and prices)
were retrieved from the MHS computerized database.
This database includes information on all medications
dispensed to MHS beneficiaries starting January 1998 up
to end of 2014, classified into 56 pharmacological
groups. We included in our analyses the 10 major drug
classes that accounted for about three quarters of the
total drug expenditure in 2014: Immunosuppressants,
anti-cancer drugs, immuno-stimulants, antiviral drugs,
anti-diabetic drugs, cardiovascular drugs, anticoagulants,
enzyme replacement agents, lipid-lowering drugs, and
antibiotics.
Data analysis and statistics
Data on drug expenditure were expressed in New Israeli
Shekels (NIS) and matched to the Israeli 2014 Cost of
Health Index. For the years 1998–2014 (observation
period), we calculated the expenses for each drug cat-
egory per HMO member, thus accounting for the grow-
ing number of HMO members during this period.
Changes in annual drug expenses per HMO member
were not normally distributed, and were therefore
expressed as medians and interquartile ranges, with non-
parametric tests (Kruskal-Wallis) used for comparison
among different drug categories. Additionally, we com-
pared the distribution of expenditures for the 10 drug
classes as proportions of total drug expenditures at the be-
ginning (1998) and the end of the observation period
(2014) using χ2-test. For all statistical analyses, P-values
<0.05 were considered significant. Statistical analyses were
performed using SPSS statistical software (SPSS v.22,
IBM® SPSS® Inc., Chicago, IL). The study was approved by
the MHS institutional review board.
Results
Global drug expenditure
During the study period, the number of MHS beneficiar-
ies increased by 88.6 %, from 1.141 to 2.151 million. The
total annual drug purchase expenditures increased by
108.2 %, from NIS 489.9 million to NIS 1,020.2 million.
Accordingly, the average annual drug expenditure per
beneficiary increased only slightly, from NIS 429.56 in
1998 to 474.32 in 2014 (a rise of 10.4 %). The ten major
pharmacological groups accounted for 58.0 % and
77.8 % of total drug cost in 1998 and 2014, respectively.
Trends in drug expenditure by drug category
Costs per beneficiary in 1998 were dominated by cardio-
vascular medications (16.0 % of total cost), followed by
antibiotics (9.1 %) and lipid-lowering drugs (7.1 %).
Costs of cancer agents accounted for 6.8 % of drug ex-
penditure in 1998, but rose steadily to become the lar-
gest expenditure for a single drug class starting in 2002.
By 2014, antineoplastic drugs accounted for 30.2 % of
total drug expenditure, while expenditure for some other
drug classes (e.g., cardiovascular and lipid-lowering
drugs and antibiotics) decreased constantly. Accordingly,
the overall distribution of drug expenditures for different
drug classes was significantly different when comparing
the beginning (1998) with the end (2014) of the observa-
tion period (P < 0.001; Fig. 1).
Differing trends in drug expenses during the observa-
tion period were also evident when examining the an-
nual changes in drug expenditures. The median annual
increase in drug expenses per beneficiary during the ob-
servation period differed significantly among drug clas-
ses (overall Kruskal-Wallis P < 0.001; Fig. 2).
For cancer drugs, expenses increased by a median of
NIS 6.18 (IQR, 1.70–9.92) per HMO beneficiary each
year, an annual increase that was more than two-fold
higher compared to that of immunosuppressants (NIS
2.81; IQR, 0.58–7.43), but the difference was not statisti-
cally significant (Mann-Whitney test for comparison be-
tween these two drug classes, P = 0.13).
Discussion
Our study demonstrates that expenditures for cancer
agents have been rising constantly over the last decade,
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Fig. 2 Median annual change in net drug expenses per HMO member for different drug classes between 1998 and 2014. Changes in expenditure
were significantly different among drug classes (P < 0.001). Bars denote the median, error bars the 75 % percentile
Fig. 1 Distribution of drug expenditure for ten major drug classes per HMO member in 1998 and 2014. The overall distribution differed
significantly between 1998 and 2014 (P < 0.001)
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offsetting savings for the majority of medications used to
treat other acute and chronic medical conditions. In fact,
by the end of study period approximately a third of all
MHS drug expenditure was accounted for by anti-cancer
drugs.
In this study, we did not attempt to identify the contri-
bution of specific reasons for the increasing expenditure
for oncological therapies, e.g., increasing drug prices, in-
creasingly complex (and therefore more expensive) treat-
ment regimens, or an increasing proportion of patients
treated, either because of changes in cancer prevalence/
detection or changes in eligibility criteria for cancer.
However, the overall age-adjusted rates of invasive tu-
mors in males and females have changed only minimally
during the study period [6]. Moreover, all therapies
included in the health basket follow internationally ac-
cepted evidence-based guidelines.
One likely reason for the sharp increase in expendi-
tures for cancer agents is the increasing approval of ex-
pensive biological and targeted therapies in this field
(e.g. monoclonal antibodies and modern tyrosine kinase
inhibitors) [7]. This trend is likely to continue with the
inclusion of costly checkpoint inhibitors (Programmed
Death-1 [PD-1] inhibitors) in the national health basket
in 2015 (i.e., after the end of the study period). Biologic
drugs also contributed to the increased drug expenditure
for autoimmune conditions in our study since 2006, par-
alleling their introduction for treatment of inflammatory
bowel diseases, rheumatic diseases, and other auto-
immune disorders, and challenged by health organiza-
tions’ difficulties to incorporate biosimilars.
Rising costs of cancer drugs should be viewed with
concern in light of the fact that cancer incidence is ex-
pected to rise worldwide, from 10.4 million newly
diagnosed patients annually in 2000–25 million in 2030
[8], with more than 70 % of cases occurring in low- and
middle-income countries [9].
The increase in total drug expenditure per beneficiary
in our study (a rise of 10.4 % over 16 years) was modest
compared to other developed countries, e.g., 5.5 % and
4 % in Western European countries and Japan over
shorter time periods, respectively [4, 5]. This difference
reflects extensive generic drug use in Israel for numer-
ous medical conditions compared with other Western
countries [4]. In our study, the major savings in expend-
iture for antibiotics, cardiovascular drugs and lipid low-
ering agents were most noticeable after 2001 (Fig. 3),
coinciding with the HMO-wide implementation of cost
containment methods including preferred drug lists,
generic substitution, pre-authorization of selected ex-
pensive drugs, and advanced methods to assess and con-
trol drug prescription and dispensing.
The allocation of limited public resources to various
diseases has to be judged objectively in view of the ex-
pected benefit to patients. During the years 1970–2000,
the life expectancy of U.S. Americans increased on aver-
age by 6 years; only 6 months were attributed to anti-
neoplastic therapies, while over 4 years were attributed
to pharmacological interventions for cardiovascular
diseases and metabolic conditions [10]. Many drug treat-
ments for cardiovascular diseases and metabolic condi-
tions are available as generics, and “me-too” or
“glorified-me-too” drugs were released, increasing com-
petition and diminishing overall costs for these pharma-
ceutical groups. Notwithstanding, public awareness of
the needs of cancer patients in Western countries, where
malignancy is the leading cause of death, increases the
pressure on regulators to approve new and expensive
Fig. 3 Mean annual net expenditure per HMO member for the major drug classes. The listed drug classes comprised together 77.8 % of the total
drug expenditure per MHS member in 2014
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cancer agents, sometimes with only limited evidence of
cost-effectiveness [11, 12]. Moreover, data on post-
marketing effectiveness, including the effect on mortality
in cancer patients, is sparse, precluding the assessment
of real-life public benefit.
Our study has several limitations. Firstly, MHS ensures
a relatively young population [16 % are ≥55 years of age,
as compared to 19.1 % in the general Israeli population
[13]. Our study may therefore underestimate the ex-
penditure for antineoplastic agents in aging populations.
As mentioned above, we normalized expenditure per
HMO beneficiary and not per patient treated, which
greatly underestimates the real rise in drug expenditure
per cancer patient. However, the focus of this study was
the changing burden of drug expenditure across differ-
ent drug classes on an HMO’s medication budget, and
not expenditures per patient for individual patient
groups. Our approach better captures the true impact of
expenditures for a pharmacological class on the budget,
since it reflects both drug costs per patient and the
prevalence of the disease group. For instance, drug ex-
penditure for a patient with Gaucher disease requiring
enzyme replacement therapy is higher than for the aver-
age oncological patient, yet the burden of Gaucher pa-
tients on the medication budget is lower (5 % of total
expenditures) due to the low number of Gaucher pa-
tients compared to that of oncological patients (30 % of
total expenditures). We also did not consider expend-
iture for drugs used in oncology supportive care, such as
agents to control chemotherapy-induced nausea and
vomiting, narcotics and other analgesics, and growth fac-
tors (e.g. G-CSF), and our data therefore underestimate
the real malignancy-related drug expenditure for cancer
patients. A few oncological medications also have spe-
cific non-oncological indications, and are covered by the
health basket according to specified criteria as third- or
fourth-line drugs for such non-oncological indications.
In this database study, we categorized these medications
by their main indication into the oncological drug class,
since this represented their by far most common use.
For instance, the anti-CD20 monoclonal antibody rituxi-
mab was reimbursed in more than 90 % of all cases for pa-
tients with hematooncological indications, and only in a
minority for patients with non-oncological indications,
such as rheumatoid arthritis or immune thrombocytopenia.
Thus, this misclassification is not expected to greatly affect
our findings.
Practical solutions for reducing the costs of cancer
therapies should consider different strategies beyond the
well-established formulary approach, including imple-
mentation of pharmacoeconomic evaluation in health
care decision-making. A number of strategies have been
suggested, including sequential monotherapy use in the
palliative setting (instead of combination therapy) and
lowering the doses of anticancer agents when appropri-
ate and supported by data [1]. Another well-known ap-
proach is the Technology Appraisal Program of NICE in
the United Kingdom which often considers the cost per
QALY ratio (quality adjusted life years) [14–16]. The
measure of QALY is widely used as it takes into account
not only life expectancy but also quality of life, which is
often significantly impaired in cancer patients. Other po-
tential solutions beyond cost sharing (i.e., increasing the
contributions to insurance premiums and selection of
insurance plans with higher copayment) include risk
sharing [17] and conditional reimbursement [17, 18].
Risk sharing refers to financial compensation of health
insurers by drug companies in cases where the post-
marketing drug effectiveness was inferior to the benefits
expected from the drug dossier submitted to the regula-
tory authorities for drug approval. Conditional reim-
bursement refers to temporary conditional approval of
an index drug therapy for a limited period of time, after
which its approval is reevaluated as a condition for per-
manent reimbursement.
Conclusions
Our data suggest that despite successful MHS cost con-
tainment methods to control modern medication ex-
penditure and thus provide updated treatment for
chronic medical conditions to larger patient populations,
the economic burden of cancer medications on the drug
budget increases constantly, potentially compromising
the total drug budget. Our findings suggest that a com-
prehensive cost-benefit assessment of cancer drug ther-
apy should guide oncological drug approval in public
health care organizations, and methods to control and
limit drug cost should be coordinated between health
care providers, pharmaceutical companies, and policy
makers.
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